Block analysts lift targets after earnings; stock lags peers on the week

Block, Inc. reported Q3 results on November 3 and walked away with a clutch of analyst upgrades the following morning, yet the stock closed at $76.00, up just 1.5% on the week against a peer median gain of roughly 3% to 10%.

The analyst reaction to earnings was broadly positive and notably one-directional. BofA Securities raised its target to $117 from $115, keeping its Buy. TD Cowen lifted to $109 from $105. Susquehanna went to $110 from $100. RBC Capital moved to $103 from $95. Morgan Stanley, which downgraded to Equal-Weight just days before the print, raised its target to $82 from $80 while staying on the sidelines. The pattern is clear: even the cautious camp is conceding the numbers were better than feared. The consensus mean target stands at $97.91, implying roughly 29% above current levels, though that figure remains anchored to analyst resets pre-earnings and will shift as more updates land. Nine analysts hold a Buy-equivalent rating, nine are at Hold, leaving the desk split in a way that rarely resolves quickly.

The lending market tells a story consistent with no meaningful short pressure. Availability is effectively unlimited, with hundreds of millions of shares available to borrow against roughly 13.7 million shares currently short, 2.5% of the free float. Borrowing costs have fallen sharply, down 37% over the past week to 0.27%, the lowest level in the 30-day window. Short interest itself has edged down about 0.4% over the week and is flat to slightly lower on the month once the mid-October bulge, which peaked around 14.4 million shares, is stripped out. Options positioning offers no additional tension: the put/call ratio of 0.675 is essentially glued to its 20-day average of 0.674, a z-score of 0.13, and nowhere near the 52-week defensive extreme of 0.81. The ORTEX short score of 33 ranks in the 55th percentile, unremarkable. Taken together, positioning looks benign rather than charged in either direction.

The valuation picture is mixed on the numbers but stands out on relative ranking. The EV/EBITDA multiple has contracted about 2.6% over 30 days to 8.5x. The price-to-book is 1.75x. The earnings yield of 6.6% ranks in only the 36th percentile, while the EV/EBIT factor scores in the bottom 5% of the universe, flagging that the stock is not cheap on operating earnings. The analyst recommendation differential, however, ranks in the 93rd percentile, the highest factor in the snapshot, reflecting how far the consensus target sits above the current price relative to the broader universe. That gap is the number most likely to close, one way or another, as post-earnings revisions filter through over the coming days.

One insider angle is worth noting, though it carries a clear caveat. Director Anthony Mathew Eisen sold 6,000 shares on each trading day from October 15 through October 28, a total of 60,000 shares at prices ranging from $74.44 to $80.43. Every one of those transactions was executed under a pre-arranged 10b5-1 trading plan. Planned sales of this mechanical regularity carry almost no informational content about conviction on the stock. Net insider activity over the past 90 days is negative at roughly 310,000 shares sold and $24.4 million in net value, almost entirely attributable to this programmatic selling. Among major institutional holders, Capital Research and Management added 801,000 shares in the most recent quarter to 3.54% of shares, the largest active-manager increase in the top-15 list. Columbia Management added 1.6 million shares, taking its stake to 1.4%. Jack Dorsey remains the largest single holder at 8.1% of shares, unchanged.

The one genuinely anomalous data point from ORTEX Alt Data is retail attention. The Wikipedia pageviews and ORTEX page-traffic composite reached 5.67 standard deviations above its 90-day average as of October 25, flagged previously and still the highest reading in the tracked window. That spike pre-dated earnings, and the degree to which retail attention has since normalised, or persisted, will show in the next few days of data. The next earnings date is February 24, 2027. Between now and then, what matters most is whether the analyst target upgrades from post-earnings notes translate into an improvement in the hold-versus-buy split, and whether the stock can close the gap to the $82 Morgan Stanley target that currently sits just above current levels.